BCL2突变在接受利妥昔单抗治疗的滤泡性淋巴瘤患者中不提示不良预后
在PRIMA随机试验中,252例接受免疫化疗的滤泡性淋巴瘤患者中,54%检出BCL2氨基酸改变突变,这些突变可能由AICDA过度活化介导。中位随访6.7年,BCL2突变对总生存或无进展生存均无影响。
要点
- PRIMA试验中252例接受免疫化疗的滤泡性淋巴瘤患者,54%检出BCL2氨基酸改变突变。
- BCL2突变可能由AICDA过度活化介导,且多位于N端和柔性环区,BH1、BH2、BH3基序突变频率较低。
- 中位随访6.7年,BCL2突变对总生存和无进展生存均无影响。
核心结论
- 在接受含利妥昔单抗方案治疗的滤泡性淋巴瘤患者中,BCL2突变不提示不良预后。
研究设计与样本
- PRIMA随机试验中252例接受免疫化疗的滤泡性淋巴瘤患者的前瞻性队列。
- 采用DNA靶向测序方法检测BCL2突变。
主要发现
- 135例(54%)患者检出BCL2氨基酸改变突变。
- BCL2突变可能由t(14;18)易位背景下AICDA过度活化介导。
- BCL2变异在BH1、BH2和BH3功能基序中的频率低于N端和柔性环区,且多为保守性氨基酸改变。
- 中位随访6.7年,BCL2突变对总生存和无进展生存均无影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
引用
- Huet S, Szafer-Glusman E, Tesson B, et al. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. Am J Hematol. 2017. PMID: 28247997. doi:10.1002/ajh.24701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。